Correlation Between Reduced IL-1β Levels in Acne Lesions and the Decrease in Acne Inflammatory Lesions Following Topical Vitamin D Administration: A Double-Blind Randomized Controlled Trial
Nelly Herfina Dahlan,Irma Bernadette Sitohang,Wresti Indriatmi,Heri Wibowo,Liani Elisabeth Enggy
DOI: https://doi.org/10.2147/ccid.s475068
2024-10-01
Clinical Cosmetic and Investigational Dermatology
Abstract:Nelly Herfina Dahlan, 1, &ast Irma Bernadette S Sitohang, 1, &ast Wresti Indriatmi, 1 Heri Wibowo, 2 Liani Elisabeth Enggy 3 1 Department of Dermatology and Venereology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; 2 Department of Integrated Laboratory, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; 3 Faculty of Medicine, Hasanuddin University, Makassar, Indonesia &astThese authors contributed equally to this work Correspondence: Irma Bernadette S Sitohang, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Jalan Salemba Raya No. 6, Jakarta, 10430, Indonesia, Email Background: The inflammatory process in acne vulgaris (AV) is characterized by the upregulation of specific pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and IL-8, within sebocytes and keratinocytes. Sebocytes have been identified as target cells for bioactive vitamin D. Experimental studies on animal models have demonstrated the potent comedolytic effects of topical vitamin D. However, further research is required to specifically evaluate the impact of vitamin D on inflammatory lesions in acne vulgaris (AV). Objective: To evaluate the effectiveness of topical vitamin D in treating acne vulgaris (AV) lesions by investigating its anti-inflammatory effects on pro-inflammatory cytokine modulation, specifically assessing the correlation between IL-1β levels in acne lesions and the reduction in AV severity. Materials and Methods: This study is a double-blind, randomized, placebo-controlled clinical trial with a 2-arm design over an 8-week intervention period. Participants were randomly assigned to either the topical vitamin D group (cholecalciferol 50 mcg) or the topical placebo group, with each group comprising 32 subjects. All participants received concomitant treatment with topical adapalene 0.1%. Cytokine levels within acne lesions were assessed using Luminex Polystyrene Screening Assays to detect and quantify IL-1β levels. The effectiveness of the treatment was evaluated by monitoring the reduction in the number of inflammatory lesions, while the safety of topical vitamin D was assessed by documenting and analyzing any reported side effects. Results: The study found a significant correlation between the reduction in IL-1β levels within acne lesions and the decrease in moderate and severe inflammatory lesions in acne vulgaris (p = 0.028). The topical application of vitamin D led to a significant reduction in inflammatory AV lesions (p = 0.045). No significant topical side effects were observed in either the vitamin D or placebo groups. Conclusion: This study demonstrates that the topical administration of vitamin D in acne vulgaris (AV) lesions is effective in reducing pro-inflammatory cytokine levels within acne lesions and in decreasing the severity of AV. Trial Registration: NCT05758259. September 5, 2022. Keywords: acne vulgaris, topical vitamin D, IL-1β, Luminex Acne vulgaris (AV) is an inflammatory disorder affecting the pilosebaceous gland unit. The etiology of AV is multifactorial, involving an increased rate of sebum production, endocrinological influences such as androgens, abnormal keratinization of the follicular infundibulum, proliferation of Cutibacterium acnes , and subsequent inflammatory responses. 1,2 The inflammatory process plays a critical role in the pathogenesis of acne vulgaris (AV). 2 Locally activated infiltrating cells release cytokines, including interleukin 1β (IL-1β), IL-6, IL-8, IL-12, and tumor necrosis factor α (TNF-α), from macrophages, keratinocytes, and sebocytes. Among the proinflammatory mediators, IL-1β has been detected in various active forms within acne lesions. IL-1β is a cytokine that plays a crucial role in regulating the inflammatory response and serves as an initial mediator released during both acute and chronic inflammation. 3,4 Kistowska et al 5 states that the production of IL-1β by C. acnes -exposed monocytic cells requires activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, triggered by a wide variety of signals, including danger-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and bacterial toxins. This suggests that IL-1β could be a promising therapeutic target in the treatment of AV. 6,7 Vitamin D regulates various skin functions, including keratinocyte proliferation, differentiation, apoptosis, and immunoregulation. Additionally, it poss -Abstract Truncated-
dermatology